2026-01-28 - Analysis Report
**Company Overview:** Merck is a healthcare and pharmaceutical company.

**1. Return Rate Comparison:**

* Cumulative return of review stock = 69.98%
* Cumulative return of comparison stock (S&P 500, VOO) = 128.51%
* Divergence (max: 48.40, min: -96.80, current: -58.40, relative divergence: 26.40%)

**2. Stock Price Fluctuations:**

* Close = $107.92
* Last-market change = 0.48% ($0.48)
* 5-day SMA = $108.76
* 20-day SMA = $108.62
* 60-day SMA = $100.60

**3. RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI) = 0.70 (Medium Investment)
* RSI = 47.18
* PPO = -0.62
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change = -1.80 (worsening)
* 7-day Rank change = 3 (rank up)
* 7-day Dynamic Expected Return change = 21.80 (improving)
* Expected Return (%) = -3.30% (Expected excess return compared to S&P 500 if invested long-term)

**4:2) Recent Events and Significant News Analysis:**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
	+ Opinions: 27
	+ Target Price (avg/high/low): 117.30 / 135.00 / 86.00

**5. Recent Earnings Analysis:**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | $17.28 B |
| 2025-08-05 | 1.76 | $15.81 B |
| 2025-05-02 | 2.01 | $15.53 B |
| 2024-11-06 | 1.25 | $16.66 B |
| 2025-11-05 | 1.25 | $16.66 B |

**Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis:**

* Strong quarterly earnings and revenue growth in 2025
* Consistent profit margins and ROI in 2025
* Relative divergence in RSI and PPO indicators indicates a potential rebound
* Expected return is negative, but expected excess return compared to S&P 500 is -3.30%
* Market risk indicator is at medium level
* Buy rating with a target price of $117.30 and a high estimate of $135.00
* Recent events suggest potential growth in 2026
* 7-day Dynamic Expected Return shows improvement

**Summary:**

Merck has demonstrated strong quarterly earnings and revenue growth in 2025, maintaining consistent profit margins and ROI. However, the relative divergence in RSI and PPO indicators suggests a potential rebound, and the expected return is negative. The market risk indicator is at medium level, and the Buy rating with a target price of $117.30 and a high estimate of $135.00 indicates potential growth. Recent events suggest further growth in 2026, and the 7-day Dynamic Expected Return shows an improvement.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.